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Abstract 
 
Background: Schizophrenia is a debilitating psychiatric disease that can cause many symptoms including 
attention deficits and cognitive impairments. Currently there are no effective treatments for the 
cognitive symptoms in schizophrenia. There is a large population of smoking schizophrenics, which has 
pushed research to examine a possible correlation between nicotine and schizophrenia. Research has 
found that a possible cause for this correlation is self-medication: given that nicotine may enhance 
cognition. Research has now taken it one step further and examined the effect of nicotine 
administration on attention performance.  
 
Method: An exhaustive search using MEDLINE-PubMed, MEDLINE-Ovid, CINAHL, Google Scholar, and 
Web of Science was performed using the keywords: schizophrenia, nicotine, patch, and cognition. 
Eligibility criteria were applied to refine the search further. Articles were assessed for quality using 
GRADE criteria. 
 
Results: After completing the search, three articles were selected according to the inclusion and 
exclusion criteria. All studies were RCTs and compared the effects of the transdermal nicotine patch 
with schizophrenic participants versus controls. One study compared smoking participants, another 
compared non-smoking participants, and the last one compared both groups. All three studies support 
the hypothesis that nicotine improves the attention deficits in schizophrenia. The discussed studies 
focus on short-term effects of nicotine on attention performance, so future research should examine 
the long-term effects for safety and efficacy.  
 
Conclusion: Administration of a transdermal nicotine patch has been shown to improve attention 
performance in schizophrenics. If further research validates these findings, usage of transdermal 
nicotine patches can be considered as an alternative therapy given the ease of use and availability.  
 
Keywords: Schizophrenia, nicotine patch, attention, and cognition 
 
  
  
 
4 
Acknowledgements 
 
To our family:  We could not have done this without you. Thank you for supporting us through our 
journey.  
  
 
5 
Table of Contents  
 
Biography……………………………………………………………………………………………………………………………………………2 
Abstract………………………………………………………………………………………………………………………………………………3 
Acknowledgements…………………………………………………………………………………………………………………………….4 
Table of Contents……………………………………………………………………………………………………………………………….5 
List of Tables……………………………………………………………………………………………………………………………………….6 
List of Abbreviations……………………………………………………………………………………………………………………....…..6 
Background…………………………………………………………………………………………………………………………………………7 
Methods……………………………………………………………………………………………………………………………………….…….8 
Results………………………………………………………………………………………………………………………………………….…….8 
Discussion………………………………………………………………………………………………………………………………..………..14 
Conclusion……………………………………………………………………………………………………………………………….………..17 
References………………………………………………………………………………………………………………………………….……..18 
Tables………………………………………………………………………………………………………………………………………………..19 
 
  
 
6 
List of Tables 
 
Table I. GRADE Quality of Assessment: Characteristic of Reviewed Studies 
 
 
List of Abbreviations 
 
GRADE   grading of recommendations, assessment, development, and evaluations 
RCT   randomized controlled trial 
nACHRs   nicotinic acetylcholine receptors 
mg   milligram  
CPT-IP   continuous performance test identical pairs  
LOC   loss of consciousness  
D2 blocking  dopamine 2 receptor blocking 
CNS   central nervous system 
DSM    diagnostic and statistical manual  
  
 
7 
Nicotine’s Effect on Attention Deficits in the Schizophrenic Population 
 
BACKGROUND 
Schizophrenia is a psychological disorder that can cause hallucinations, delusions, 
disordered speech, attention deficits, and other cognitive impairments. Antipsychotics are the 
mainstay of treatment for schizophrenia; however, there are no effective medications for the 
attention deficits present in schizophrenia. Medications used in the general population for 
attention deficits have a possible interaction with the necessary antipsychotics prescribed for 
schizophrenia. Having attention deficits can cause barriers to educational performance and 
efficiency in the workplace.  This is an issue as almost one-half of homeless adults in America 
are schizophrenic.1 By treating attention deficits in schizophrenia clinicians can improve 
functionality and help patients to better cope with the disease.  
A common trend seen amongst the schizophrenic population is high rates of cigarette 
smoking. As demonstrated by the fact that 58-88% of schizophrenics smoke cigarettes 
compared to the 23% of the general population.2 Previous research has focused on determining 
the correlation of smoking in schizophrenia sufferers. Studies have found that the cause could 
be due to possible self-medication as nicotine seems to help improve cognitive symptoms in 
schizophrenia.2 Nicotine mimics acetylcholine, which binds to nicotinic receptors in the brain. 
These receptors are involved in cognition including attention. Preclinical trials have shown that 
repeated administration of nicotine causes an up-regulation of nACHRs,3 which improves the 
attention deficits.  
Many trials have examined the effect of medications such as acetylcholinesterase 
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inhibitors, nACHR agonists, and nicotine administration that effect nACHRs. There is limited 
support regarding the efficacy of acetylcholinesterase inhibitors and nACHR agonists.4 There is 
more support behind use of nicotine administration including transdermal patch, gum, and 
nasal sprays. Nicotine administration is also safe, cheap, and easy to administer. Use of nicotine 
administration through gum or nasal spray could possibly cause differing levels of nicotine 
extraction.4 Because of this, the effects of a transdermal nicotine patch in correlation to 
schizophrenic attention performance are examined. The goal of this review is to assess the use 
of transdermal nicotine patch to improve attention in the schizophrenic population.  
METHODS 
An exhaustive literature review was performed by searching MEDLINE-PubMed, 
MEDLINE-Ovid, CINAHL, Google Scholar, and Web of Science databases. The following keywords 
were used to help narrow down the results: schizophrenia, nicotine, patch, attention, and 
cognition. Reviewed articles were also used as a source for allocation of other relevant articles. 
Inclusion criteria consisted of randomized controlled trials studying a population of patients 
with clinically diagnosed schizophrenia as defined by the DSM IV or V, comparing transdermal 
nicotine patches to a placebo or absence of nicotine patch, and measuring attention deficits. 
Exclusion criteria consisted of articles not written in the English-language,that enrolled 
participants who were younger than 15 years, and that had a sample of less than 25 
participants. All relevant articles were assessed for quality using the Grading of 
Recommendations, Assessment, Development, and Evaluation.5  
RESULTS 
A total of 93 articles were found initially from database search. From the 93 articles 10 
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fit the eligibility criteria. Three articles out of the 10 were selected for review. All three articles 
are randomized controlled studies and each examined a different population. One article 
focused on smoking schizophrenics,4 another focused on non-smoking schizophrenics,6 and the 
last article compared both populations.7  
Jacobsen et al 
 In 2004, Jacobsen et al4 conducted a randomized double blind trial examining the effects 
of nicotine on brain function in smoking schizophrenics compared to smoking controls. The 
primary outcome of this trial was attention and memory. Participants were assessed by 
completing tasks while receiving an fMRI scan.4 
 There were 26 total participants in this study and all were smokers. There were 13 
participants who were schizophrenic and 13 who were controls. Recruitment of participants 
was not discussed throughout the study. Inclusion criteria were not stated as well. Exclusion 
criteria included history of head trauma, medical illnesses compromising the CNS, substance or 
alcohol abuse within 12 months, and diabetes.4 
 There were 2 trials performed in this study. All participants received both a transdermal 
nicotine patch and a placebo patch. Order of administration was randomized and double blind. 
Dosing of transdermal nicotine patch depended upon BMI. Participants with a BMI less than 26 
kg/m2 received a 28 mg nicotine patch and those with a BMI more than 26 kg/m2 received a 35 
mg nicotine patch. Scanning was done 6 hours after application of patch. During scanning 
participants performed an auditory n-back test with 2 levels of working memory load and 2 
levels of selective attention load. Participants either heard a phrase in both ears or different 
phrase in each ear (dichotic). They were then told to identify if the phrase was 1-back which is a 
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back-to-back repeat of a word or a 2-back which is a repeat that is separated by a different 
word. A total of 120 echoplanar functional images were taken per slice during the tasks. 4 
 Results showed that nicotine improved performance in schizophrenic participants. 
Specifically, there was more activation in different parts of the brain during the dichotic 2-back 
tasks while using nicotine in schizophrenic participants versus controls (p=0.03).  Dichotic 2-
back tasks were the most difficult to perform which shows the extent of the effect of nicotine. 
Also, regions of the brain showed more of an increase in activity in the nicotine patch trials 
during the high selective attention load with schizophrenic participants (p<0.01). 4 
 Limitations of this study include that all non-smokers were excluded. There is a possible 
confounder called the relief-from withdrawal phenomenon, which states that the cognitive 
enhancement seen in smokers using nicotine replacement could be due to relieving withdrawal 
symptoms instead of increasing cognitive function.8 The sample size was quite small, so there is 
a threat to precision of the outcome. Also, the chemical breakdown of nicotine (plasma 
cotinine) and serum nicotine was higher in schizophrenic participants versus controls before 
administration of patches. This could pose a possible confound as to why they performed 
superior to controls. 4 
Barr et al 
Barr et al6 conducted a randomized, double-blinded, placebo-controlled, crossover trial 
in 2008 examining the effects of transdermal nicotine patch on cognition in nonsmokers with 
schizophrenia versus nonsmoker controls. The primary outcome focused on in this trial was 
attention performance, which was assessed by using CPT-IP testing.6 
Schizophrenic participants in the study were recruited from an urban community mental 
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health clinic. Control participants were enlisted from advertising in both local press and on the 
internet. Inclusion criteria included participants aged 18-65 years, non-smokers for over 3 
months prior to enrollment, and patients with diagnosis of schizophrenia or schizoaffective 
disorder by DSM IV. Exclusion criteria included substance abuse or dependence, any lifetime 
diagnosis of cognitive impairment secondary to head injury, dementia, use of investigational 
medication in the past month, current diagnosis of major depressive disorder, current unstable 
medical illnesses, and any recent schizophrenia medication changes or changes in disease. 
There were 60 total participants who met criteria, 28 were schizophrenic and 32 were 
controls.6 
Three visits were conducted in this study. The first visit was intended to set a baseline 
for participants and training. Participants were then randomized blindly using a computer 
generated random number sequence. This was done to determine which patch they received 
first, active patch or placebo patch. The next 2 visits were separated by 1-2 weeks. Participants 
received either 2 patches of the 7 mg transdermal nicotine or placebo and then completed CPT-
IP testing 3 hours later. During testing, participants were asked to identify 2 identical pairs in 
sequence by clicking the computer mouse with their dominant hand.  The following outcomes 
were measured: signal to noise, correct hits, hit time reaction, standard deviation of hit time 
reaction, and errors such as false alarms.6 
Results of the repeated measures ANOVA showed improved performance for both 
groups using a nicotine patch. There was a reduced hit reaction time (p<0.0001) and reduced 
random errors (p<0.001). In addition, there were greater reductions with schizophrenic 
participants taking nicotine patch. The calculated 95% confidence interval was 342-742 with a 
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mean of 542 for schizophrenic participants after placement of nicotine patch. Findings were 
statistically significant.6 
Limitations of this study are that only non-smokers were included in order to prevent 
confounders. Previous research focused on studying smokers exclusively and found that the 
nicotine patch could be treating withdrawal symptoms instead of improving cognition. Because 
of this, the focus of this study is on non-smokers. However this can be a limitation, as both 
groups were not compared in this study. Also the control group had participants that were 
significantly younger, had a higher IQ, and a lower rate of previous smoking. In addition, 
medications taken by schizophrenics were not controlled. Nicotine could be improving 
impairments caused by anti-psychotic medications rather than improving schizophrenic 
attention deficits.6 
Petrovsky et al 
 Petrovsky et al7 conducted a randomized, double-blinded, placebo-controlled, crossover 
study in 2013 examining the effects of nicotine on oculomotor performance. This study 
compared 4 groups including smoking schizophrenics, non-smoking schizophrenics, smoking 
controls, and non-smoking controls. They used oculomotor testing as a surrogate outcome for 
attention performance.7 
 Schizophrenic participants were recruited from the outpatient clinic of the University 
Hospital, Bonn. Controls were recruited from local advertisements and city registry. Inclusion 
criteria were: smokers and non-smokers, both male and female participants, ages 15-55 years 
old, and participants diagnosed with schizophrenia or schizoaffective disorder according to DMS 
IV. Exclusion criteria included: head injury with LOC > 5 min, life-time history of alcohol or 
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substance abuse dependence, history of neurologic illness or other severe medical condition, 
clinical instability, recent change in medication <6 weeks, anticholinergic medication, severe 
obesity of a BMI >30 kg/m2, and uncorrected visual impairments. There were 48 total 
participants after applying the criteria. There were 22 schizophrenic participants, consisting of 
12 smokers and 10 non-smokers. There were 26 controls, consisting of 14 smokers and 12 non-
smokers.7 
 This study included a total of 2 testing days. Each participant had 1 trial with placebo 
patch and 1 trial with nicotine patch. The order of which patch came first was randomized. The 
patches were dosed dependent upon whether the participant smoked or did not smoke.  
Participants who smoke received a 14 mg transdermal nicotine patch and non-smoking 
participants received a 7 mg transdermal nicotine patch. Oculomotor testing was completed 3 
hours after application of patch. Oculomotor, or saccadic eye movement, is under control of 
the executive functioning of the brain and it is used to estimate attention performance. Tasks 
completed during oculomotor testing consisted of performing 1 block of both standard and 
delayed antisaccade and prosaccade trials. During standard trials, participants were told to 
fixate on a center cross and subsequently a target dot and wave tone would appear in the 
periphery. Participants were told to then move their eyes either towards the target in the 
prosaccade trials or away from the target in the antisaccade trials. In delayed trials the 
peripheral target would appear in the periphery but participants were told not to move their 
eyes until the delayed wave tone appears.7 
 Nicotine reduced errors during standard antisaccade trials in both controls and 
schizophrenic participants equally (p=0.02). Because of this, antisaccade performance was 
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found to be improved. There was no correlation between prior smoking status and antisaccade 
performance (p=0.10).  This implies that nicotine has an equal effect on cognitive performance 
in both smoking and non-smoking participants. Antisaccade latencies were decreased in the 
nicotine trials (p = 0.0003), which suggests improved attention performance. Antisaccade error 
rate was positively correlated with plasma cotinine levels in standard trials (p = 0.02). This data 
implies there is a dose dependent response with nicotine and antisaccade performance.7 
 Limitations of this study include using surrogate outcomes. Oculomotor testing has been 
shown to be an effective testing measure for cognitive function but is not specific to attention. 
Because this is not a direct measure there is some indirectness of the results. In addition, the 
range of saccade eye movement was so narrow that a small change could be considered 
statistically significant. This can make the outcomes seem larger than they really are. Lastly, 
smoking participants were deprived of smoking overnight so there is a possibility for relief of 
withdrawal symptoms versus true cognitive enhancement. Petrovsky et al suggests future 
research to have smoking participants deprived for only 2 hours compared to overnight.7 
DISCUSSION  
All studies4,6,7 reviewed suggest an increase in attention performance with nicotine 
patch in schizophrenic populations. This provides the starting point to establishing a simple 
form of treatment for attention deficits in schizophrenics. Jacobsen et al4 found that non-
smoking schizophrenics and controls had increased brain activity and attention performance 
with 14-gram nicotine patch administration. Barr et al6 found that smoking schizophrenics and 
controls had improved attention performance with nicotine patches dosed based upon BMI. 
Petrovsky et al7 compared both nonsmoking and smoking schizophrenics and controls. This 
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study found that schizophrenics had an increased performance with nicotine patch dosed 
dependent upon smoking status. These three studies show there is a possible correlation 
between the usage of a nicotine patch and improving attention deficits in both non-smoking 
and smoking schizophrenics. Because of these results, administration of transdermal nicotine 
patch could be considered for off-label treatment of cognitive symptoms in schizophrenia after 
additional research is conducted.  
There was some variability across studies including the amount of nicotine given in each 
patch and type of testing administered. Jacobsen et al4 used a patch based on BMI and the 
results of this study only showed improvement in schizophrenic participants rather than all 
groups as found in Petrovsky et al7 and Barr et al.6 Petrovsky et al7 dosed based upon smoking 
status and Barr et al6 used a standard 14 mg transdermal patch for all groups. Given there was 
variability on dosing of transdermal nicotine patch in all three studies, future research should 
focus on determining adequate dosing of therapeutic nicotine patch.  In addition, all three 
studies included different types of cognitive testing administered and could provide some 
variation in the results. It is hard to compare such differing cognitive testing especially with 
surrogate testing in Petrovsky et al7 in comparison to the direct testing measures used in Barr et 
al6 and Jacobsen et al.4 There is some benefit in using different measures to assess the cognitive 
function in that attention is a broad skill; however, it is difficult to assess whether all testing is 
measuring the same cognitive components.   
 There is also a risk of bias considering the small sample size of all studies reviewed. 
Using a small sample size poses the risk of not representing the schizophrenic population 
accurately. With a small sample size study results can be found to not be statistically significant 
  
 
16 
because small changes cause larger deviations. Petrovsky et al7 possibly has a risk of selection 
bias given schizophrenic participants were only recruited from the out-patient clinic of the 
University Hospital, Bonn. Barr et al6 has a risk of selection bias as schizophrenic participants 
were only recruited from the out-patient population of an urban community mental health 
clinic. Jacobsen et al4 did not specify where participants were recruited from so bias cannot be 
ruled out. Future research should focus on studying a more diverse and larger sample size. 
There are also some major confounders in the discussed studies. Firstly schizophrenic 
participants were taking different types and doses of D2 blocking anti-psychotics in each study. 
Different doses of dopamine antagonists can cause different levels of cognitive enhancement 
from nicotine. Also, nicotine could be treating the dopamine antagonist related to cognitive 
deficits rather than schizophrenic specific cognitive deficits.6 Future research should control for 
this or study the interaction between dopamine antagonists and nicotine. Another confounder 
is the relief-from withdrawal phenomenon. As previously stated, this implies that using nicotine 
replacement in smokers may be helping withdrawal symptoms rather than being true cognitive 
enhancers.6 Future research should take this into account when studying the smoking 
populations and provide less time deprived of smoking before testing.  
In addition, all studies discussed only examine the short-term effects of nicotine on 
cognition and attention.3 Smokers develop tolerance to nicotine overtime so the attention 
effects seen in these studies may not last. If tolerance does occur with therapeutic nicotine 
patch administration, providers would have to continue to increase dosage and there could be 
risks with this. Nicotine patches are currently used for smoking cessation as short-term therapy 
so the long-term effects have not been established. Future research should emphasize long-
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term efficacy and safety of nicotine.  
Clinicians could consider the possibility of nicotine patches as therapeutic treatment for 
attentional symptoms of schizophrenia once future research has defined dosing and long-term 
effects. Usage of the transdermal nicotine patch could provide an easy and inexpensive way to 
support schizophrenic attention deficits in order to improve their functionality in society. Usage 
of transdermal nicotine patch can also help with smoking cessation in the schizophrenic 
population. By addressing attention symptoms providers can prevent the self-medication 
through cigarette smoking and decrease the many complications that come along with 
smoking. Overall transdermal nicotine patches could be considered as a reasonable treatment 
option after research studies the relationship between schizophrenia and nicotine in depth.  
CONCLUSION 
According to the articles reviewed, nicotine patch administration has a positive 
correlation with attention performance in the schizophrenic population. The long-term effects 
are not clearly established but research suggests short-term improvement of schizophrenic 
attention deficits. This correlation has been shown to occur in both smoking and non-smoking 
schizophrenics, which indicates nicotine as a true attention enhancer.  Results did not indicate a 
profound change in performance; however, all three studies resulted in some improvement in 
attention, which suggests reliable outcomes. Future research is warranted to validate this 
correlation, identify proper dosing, and examine long-term effects of nicotine administration. 
By continuing to research on this possible method of treatment we can improve functionality in 
society and in turn decrease the high incidence of homelessness and cigarette smoking in the 
schizophrenic population.  
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TABLES 
Table 1: Quality Assessment of Reviewed Articles 
Study Design 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision Publication bias 
 
 
Jacobsen et al3 RCT Seriousa  Not Serious Not Serious Seriousb Unlikely N/A Low 
Barr et al6 RCT Not Serious Not Serious Not Serious Not Serious Unlikely N/A High 
Petrovsky et 
al7 
RCT Not Serious Seriousc Not Serious Seriousb Unlikely Dose 
response 
gradient 
Moderate 
a Didn’t address confounders related to withdrawal symptoms 
b Small sample size was used 
c Surrogate outcomes were used 
 
